Valuation: Relmada Therapeutics, Inc.

Market Cap 573M 500M 462M 426M 802M 55.15B 820M 5.52B 2.17B 27.01B 2.15B 2.1B 92.99B P/E 2026 *
-6.6x
P/E 2027 * -5.51x
Enterprise Value 573M 500M 462M 426M 802M 55.15B 820M 5.52B 2.17B 27.01B 2.15B 2.1B 92.99B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
97.1%
Yield 2026 *
-
Yield 2027 * -
1 day-4.03%
1 week-18.25%
Current month-24.28%
1 month-20.61%
3 months-29.95%
6 months+32.99%
Current year+8.49%
1 week 5.18
Extreme 5.175
6.58
1 month 5.18
Extreme 5.175
7.12
Current year 3.22
Extreme 3.2205
8
1 year 0.55
Extreme 0.55
8
3 years 0.24
Extreme 0.2404
8
5 years 0.24
Extreme 0.2404
38.68
10 years 0.24
Extreme 0.2404
54
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer 64 2020-10-26
Chief Executive Officer 65 2012-03-31
Director of Finance/CFO 61 2020-01-08
Director TitleAgeSince
Director/Board Member 65 2012-03-31
Chairman 81 2017-06-14
Director/Board Member 67 2015-11-11
Date Insider Type Main position Quantity % Market Cap.
12/12/25 Free

Chief Operating Officer

828,000 1.1291%
12/12/25 Buy

Chief Financial Officer

839,665 1.1450%
12/12/25 Free

Compliance Officer

828,000 1.1291%
Change 5-day change 1-year change 3-year change Capi.($)
-4.03%-18.25%+780.52%+84.51% 573M
-7.17%-2.63%+49.59%+74.24% 55.98B
+0.24%-5.62%+54.73%+125.15% 53.69B
+0.80%-6.31%+3.98%+423.29% 23.29B
-0.09%-0.01%-17.62%-14.67% 23.15B
-5.95%-0.22%+35.96%-9.58% 20.58B
-1.14%-3.16%+32.88%-28.80% 17.76B
-5.16%-7.00%+177.56%+326.39% 16.09B
-6.91%+2.40%+36.86%+636.97% 15.93B
+0.43%-1.03%+24.63%+191.40% 14B
Average -2.88%-1.44%+117.91%+180.89% 24.11B
Weighted average by Cap. -2.91%-2.20%+45.47%+156.87%

Financials

2026 *2027 *
Net sales - -
Net income -82.04M -71.7M -66.16M -60.98M -115M -7.9B -117M -791M -311M -3.87B -308M -301M -13.32B -108M -94.48M -87.19M -80.36M -151M -10.41B -155M -1.04B -410M -5.1B -406M -397M -17.55B
Net Debt - -
Logo Relmada Therapeutics, Inc.
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing therapies for central nervous system (CNS) and metabolic disorders. The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of CNS diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. Its lead product candidate, esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications. Sepranolone is its phase IIb ready neurosteroid developed for the potential treatment of Tourette syndrome and other compulsive disorders.
Employees
17
Date Price Change Volume
26-07-17 US$5.240 -4.03% 3,236,469
26-07-16 US$5.460 -12.08% 1,874,451
26-07-15 US$6.210 0.00% 985,914
26-07-14 US$6.210 -3.72% 969,111
26-07-13 US$6.450 +0.62% 2,145,431
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
5.460USD
Average target price
12.67USD
Spread / Average Target
+131.99%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. RLMD Stock